Sales & Marketing

Medical journal advertising takes center stage at the sixth-annual Doctor's Choice Awards

Don't throw out sales force effectiveness with the sales force-some sure-fire strategies

AZ interviewed physicians to determine why patients fail to take their medicine as prescribed. Unsurprisingly, affordability and patient apathy tied for top excuses. Pharm Exec talked to AZ to find out what the company is doing to boost compliance.

With the launch of Clinician 1, physician and nurse assistants now have a place to share information online. The increase in No-See doctors and general difficulty for reps to meet with prescribers might make this the opportunity for pharma to reach a major stakeholder.

To be effective, an adherence strategy must be responsive to an array of patients with different habits and medications, while providing information, encouragement, and support until adherence becomes reliable.

A DTC backlash is forcing branders to come up with new marketing approaches. Some are better than others ... much better

Pharma is looking to advertising agencies for more support, but companies are also under financial pressure, which in turn puts pressure on the agencies. Here are some ways to ease the situation

With an updated understanding of what type of patients use a brand under what clinical conditions, marketers can find ways to invigorate even a mature brand

What companies need is a LCM plan for the long haul that's strategic, funded, and includes a pipeline realignment process for every stage along the way. And they need it now

Between Congress, the courts, and consumers, DTC is having a rough year. Pharma marketers are now being pressured to delay direct-to-consumer advertising for six months. Is it time to pay more attention to educating doctors and patients?

Drugs are being mentioned more and more on TV shows. Is it just part of the script-or promotion on the part of the industry? If so, should it be regulated?

Dr. House, the lead character in TV's hit medical drama, House, is a high-prescribing diagnostician whose drug treatments can as easily kill or cure a patient. Can this be marketing?

It's management makeover time-and micromanaging is so last year.

What's the buzz all about? Word of mouth is more effective than we think.

Web analystics is helping a new generation of pharma web sites get engaged.

Enter the Maturity Matrix: the future of KOL management organization.

In an effort to give healthcare professionals and patients a one-stop source for factual drug safety information and treatment options, Pfizer has launched a handy new medicine safety Web site with a bevy of bells and whistles.

A new FDA Web site defines consumer print advertising so the general public can spot bad and good pharma ads. As a bonus, the site also serves as a checklist for pharma marketers trying not to step on any regulatory toes.

A new study finds that doctors are three times more likely to prescribe generics when they don’t have access to free samples of branded drugs.

Celebrity spokesperson Dr. Jarvik has been replaced with a Regular Joe in the latest Lipitor DTC spots. Will the switch make a difference?

The smart way to CRM is through SaaS

How will pharma fare in the new age of health and wellness marketing?

Digitas Health touts an increase in physician traffic to AstraZeneca's pain med site. The driver? An innovative piece of mail sporting a USB Web key to access product information.

A new study tracks six high-traffic drugs that are turning up on shady online pharmacies, usually at huge discounts. The conclusion: Fancy Web sites are suckering customers and costing pharma money and credibility.

Do consumers pay attention to risk information in television ads? FDA plans to find out with a study using phony ads for a nonexistent blood pressure drug.

Crohn?s disease is the topic of conversation on the first Abbott unbranded podcast. The company talks about why it went the radio route.

Bring customers back into the conversation

Seven steps you never knew that could fix the sales force

How a diabetes field team helped docs overcome the treatment gap

Bristol-Meyers Squibb will pay more than half a billion dollars to settle charges that it illegally promoted the sale of the anti-psychotic drug Abilify for off-label uses.